Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I hope you're right, with such a low OS I would have thought the price would have been a little more stable.
They did double their sales last quarter.
I'm surprised that one of the big California Medical Colleges is not heavy into testing this out.
I wonder what the cost per individual test runs?
It seems like it would be a revenue machine for any hospital that needs fast results, and pefect as part of a persons physical and maybe great for newborns.
Jim
on RB the company name is listed as "Energetics" but the symbol is the same. here's the link:
http://ragingbull.lycos.com/mboard/boards.cgi?board=EGEI
it's a good board, but as you can imagine not many posters yet. that won't last for long, imho. when word gets out on this little monster it's gonna fly. a low-floater rocket.
Haven't been able to find the board on RB. Got a link. Putting EGEI in the symbol box doesn't find one.
www.streetinvesting.com: Market Notification for eGene Inc.
Apr 07, 2006 (M2 PRESSWIRE via COMTEX) -- Streetinvesting.com is the acclaimed online financial newsletter with a distinguished aggressive research division. We have initiated this Market Notification for eGene Inc. ( EGEI ), developers of a revolutionary high-performance genetic analysis technology, after it announced that it is actively seeking potential distributors for its DNA analyzer product line to the pharmacogenetics area. Streetinvesting.com will be tracking this company attentively for the subsequent weeks because of their most recent development and keep interested investors and shareholders posted on any new findings and behind-the-scenes update. For a complimentary and comprehensive report on our current analysis and opinions of companies in this, or other sectors, please visit www.streetinvesting.com for a free membership subscription.
Dr. Ming Liu, acting CEO of the company, said: "Pharmacogenetic testing holds the promise of personalized medicine. Ideally, through testing of individual gene variations that influence drug metabolism and response, optimal dosage and drug selection will be better tailored to each patient prior to the start of therapy -- preventing adverse drug reactions and suboptimal treatment and resulting in substantial cost savings." He continued, "Our HDA-GT12(TM) analyzer is a product that we believe would be very beneficial to the pharmaceutical industries as they continue to develop drugs and therapies that may be more effective on certain sets of patients based on their genetic makeup as it relates to the drug or therapy." "Obviously one of the concerns of drug companies might be the cost involved in conducting DNA analysis on a great number of patients. That is where our analyzer could be extremely useful in that it reduces the hours needed to have a Ph.D. analyze the genetic makeup. We could see our system, which is so compact that it can sit on a desktop in the drug store, quickly identify patient genetic makeup through current available PCR amplification technology with the resulting data already in a digital format for transmission electronically." eGene currently sells its HDA-GT12(TM) in more than 100 hospitals and research centers worldwide. The company's sales are particularly strong in the Japanese and Far East markets. "We would like to be stronger in the U.S. and to that end are aggressively seeking distributors that can understand the uniqueness and potential of our product line," said Dr. Liu.
The HDA-GT12(TM) Genetic Analyzer is in use at more than 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
About eGene Inc.
eGene Inc. ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
Streetinvesting.com is issuing this release as a result of their announcement. We feel that the announcement may have an impact on shareholders and therefore issued this notification to keep investors informed in a timely manner.
Please visit www.streetinvesting.com for a complimentary subscription to access this issuance and other related in-depth articles. Please note that membership does not require credit card information nor does it require a commitment to our service.
We initiate Pre-Market Coverage Notifications as a tool to keep savvy investors informed before the bell. Therefore, there may or may not be an in-depth article about the aforementioned companies. The Pre-Market Coverage Notifications are not researched companies by our research team. It is simply a service to keep investors posted before the bell.
Please note that we are not just another mass-market advertisement website like many of the companies out there issuing alerts - we are a legitimate website where we help investors conduct their due diligence. If you have been brought here under false pretense, please let our staff know by emailing us at support@streetinvesting.com. We strive to bring true growth opportunities directly to our valued subscribers by finding undervalued and under-marketed companies and delivering our research in a timely manner. Please feel free to visit our site for more information and a free membership.
All material herein was prepared by Streetinvesting.com (Street Investing) based upon information believed to be reliable. The information contained herein is not guaranteed by Streetinvesting.com to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Streetinvesting.com is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Streetinvesting.com may receive compensation in cash or shares from independent third parties or from the companies mentioned.
Streetinvesting.com's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value.
Streetinvesting.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Streetinvesting.com undertakes no obligation to update such statements.
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
(C)1994-2006 M2 COMMUNICATIONS LTD
DNA is going to continue to play an important role in many sectors, I'm holding for a long profitable run.
eGene Actively Seeking Distributors in U.S. for Its DNA Analyzer for Design Drug Applications with Pharmaceutical Companies
IRVINE, Calif., Apr 06, 2006 (BUSINESS WIRE) -- eGene Inc. ( EGEI ), developers of a revolutionary high-performance genetic analysis technology, announced today that it is actively seeking potential distributors for its DNA analyzer product line to the pharmacogenetics area.
Dr. Ming Liu, acting CEO of the company, said: "Pharmacogenetic testing holds the promise of personalized medicine. Ideally, through testing of individual gene variations that influence drug metabolism and response, optimal dosage and drug selection will be better tailored to each patient prior to the start of therapy -- preventing adverse drug reactions and suboptimal treatment and resulting in substantial cost savings." He continued, "Our HDA-GT12(TM) analyzer is a product that we believe would be very beneficial to the pharmaceutical industries as they continue to develop drugs and therapies that may be more effective on certain sets of patients based on their genetic makeup as it relates to the drug or therapy."
"Obviously one of the concerns of drug companies might be the cost involved in conducting DNA analysis on a great number of patients. That is where our analyzer could be extremely useful in that it reduces the hours needed to have a Ph.D. analyze the genetic makeup. We could see our system, which is so compact that it can sit on a desktop in the drug store, quickly identify patient genetic makeup through current available PCR amplification technology with the resulting data already in a digital format for transmission electronically."
eGene currently sells its HDA-GT12(TM) in more than 100 hospitals and research centers worldwide. The company's sales are particularly strong in the Japanese and Far East markets. "We would like to be stronger in the U.S. and to that end are aggressively seeking distributors that can understand the uniqueness and potential of our product line," said Dr. Liu.
The HDA-GT12(TM) Genetic Analyzer is in use at more than 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP. It performs fast DNA sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
About eGene Inc.
eGene Inc. ( www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
his press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made base don management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof.
SOURCE: eGene Inc.
Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
bjedynak@janispr.com
Copyright Business Wire 2006
I'm a little upset that the MM's seem to be intent on hurting the market for ECEI then to make it.
The way last last PR read it looks like we could be in profitability this year.
What's not to love?
Jim
eGene Inc. Reports More Than 50% Revenue Growth with Optimistic 2006 Outlook
IRVINE, Calif., Apr 03, 2006 (BUSINESS WIRE) -- eGene Inc. ( EGEI ), developers of a revolutionary high-performance genetic analysis technology, announced today that its 2005 revenue has grown over 50% and gross profit margin increased 8% to 55% compared to the previous year, according to the Company's recent 10KSB.
Ming S. Liu, acting CEO of eGene, said: "During 2005, we achieved several significant financial milestones. Our sales increased 51% from 2004 to nearly $1.3 million for the year ended December 31, 2005. The Company achieved an operating profit for the fourth quarter of 2005. However, as a result of a termination agreement with the Company's former CEO as well as warrants issued for financial advisory services, which were expensed, the Company reported a net loss for the quarter."
He continued: "In the first quarter of 2006, we made several significant achievements compared to last year. Our continuing goal is to attain sustainable revenue growth through increased sales of the HDA-GT12(TM) Genetic Analyzer and its consumables to our global customers. We are preparing to launch new applications and new products in 2006. In addition to attaining more sustainable sales growth, we are also continuing to focus on improving our gross margins and controlling product costs."
The HDA-GT12 Genetic Analyzer, which is manufactured by this California-based company and currently in use at more than 100 hospitals and research centers worldwide, has been developed to use solid-state light sources and micro-optical collectors to make the system compact and affordable. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP. It performs RNA and oligonucleotide quality checks, as well as fast DNA sample screening, high-resolution DNA fragment analysis (2-5bp) and large DNA fragments analysis (up to 10Kb). The system also analyzes the quality and quantity of total RNA and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The Company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage.
About eGene Inc.
eGene Inc. focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity.
his press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof.
SOURCE: eGene Inc.
Martin E. Janis & Company Inc. for eGene Inc.
Beverly Jedynak, 312-943-1100, ext. 12
or
Andrew Ponzo, 312-943-1100, ext. 17
Copyright Business Wire 2006
Look on Raging Bull EGEI board, poster Barnee seems to have insight.
Check with my BULLS on a daily basis. Don't use it as a bible but it does help me on those stocks I have that are riding the fence. But, thanks for the referral. I interested in all "easy to read" cheat sheets. I am on a hold here as I'm very careful about tight floats which ain't easy. I'm also a news kinda guy. Helps me to know whether to hold em or fold em. The chart is unproven so little else to go on IMO. I hope to stay VERY long on this one just gotta figure out how to get started here.
fox, here's another magic 8-ball for you on EGEI:
http://americanbulls.com/StockPage.asp?CompanyTicker=EGEI&MarketTicker=OTC&TYP=S
i tend to agree with this "analysis", as any significant news ought to take EGEI past $4. we should have time to look for the pivot point, but if it is preempted with a news release, well, you know the rub: then we might get left behind.
kinda looks like we're resting on support here, doesn't it? may add a few on monday.
I agree across the board.....my trip wire is that I don't even know what this thing looks like....what makes it tick....some of which could be understandably trade secrets. How much is each unit?, Who has this technology working for them now?, Are there back orders?, Is there orientation specks for operation of analizer. Many other questions that should be addressed to management to give the investor an insight to it's reality. I'm head over heels for the concept. And that's enough to get me a foothold but I want to back the truck up too.
fox, those are my concerns as well. however, longer term i think this technology could be essential in many applications. as stated in the company's first blockbuster pr this can be used to control any viral outbreak, not just avian flu, so border crossings and airports would find it critically important. also consider its portability and the time it could save at crime scenes or during other forensic work like disaster recovery when going back to a laboratory just isn't practical. they should be promoting this technology to law enforcement as well as the medical community.
glty
This could be a flash in the pan unless news comes our way. Looks like they got a technical breakthru in speed and convenience of DNA reads and a hell of a pipeline for other breakthru uses for its analizer. Best news I can think of is the proof that their product is out there successfully being used or more hype on the threatening bird flu pandemic. Without news, the PPS will slide and the buys will be on the supports. The tight float and high demand for their technology will rocket the stock if we can get confirmation. I'm in but I gamble alot too. Sooo, good luck.
anyone have a guess where the bottom is on this leg down? i caught it from .72 to 1.86 -- that was one wild ride, believe me! i've been nibbling at it a bit since but want to pull the trigger on a lot more. any TA opinions would be appreciated. tia.
EGEI seems to have a small float, goes up immediately when news comes out then seems to taper off. They need to announce their contracts.
Hello
What about EGEI ? What is your feeling about it ?
Thnks
Bernard
OT: Yes, I am in BIGN and would've been in EGEI if I had caught the news earlier.
CTUM is my favorite right now. Believe they have the goods and are just getting started.
Hydroslotting for BIGN needs a chance to show its capabilities. All that takes time...
Interesting that so many are working on low-cost-immediate result tests. EGEI certainly has some legs.
Testing article,fyi:
http://www.collegian.psu.edu/archive/2005/11/11-29-05tdc/11-29-05dscihealth-02.asp
imo
dyodd
The HDA-GT12(TM) Genetic Analyzer
I wonder how much this machine costs and how ready a supply of them is avaibable? And how fast they could be distributed.
EGEI,
1.25 Bid.
Any thoughts on high this stock can go?
TIA,
Manny
I hear ya, just don't have the financial side of it totally down with those- this for that- stuff. I will ask someone knowledgeable who doesn't mind. No biggie, thanks for the reply. If I have straightforward explanation from them, will share it for others to over view.
Good luck to you too...
Centroid(shell) reverse-merged with BioCal and changed their name to eGene, to the best of my understanding.
I was just trying to confirm the BioCal connection to eGene since the patent is clearly assigned to BioCal.imo
dyodd
gl
polka, can you break down this for the layman investor? i.e. What it means in dollars and cents from one part to the other as stated, in brief?
DD:Just keeping it real...
...from the last 10q (filed 8/15/05)
dyodd
imo
http://yahoo.brand.edgar-online.com/fetchFilingFrameset.aspx?dcn=0001010412-05-000291&Type=HTML
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2005
(Unaudited)
1. ORGANIZATION AND INTERIM FINANCIAL STATEMENTS
Effective July 13, 2004, Centroid Consolidated Mines Co., (Centroid), which changed its name to eGene, Inc. (eGene), completed a merger with BioCal Technology, Inc., (BioCal) a private California corporation in the business of developing, manufacturing, and marketing genetic analyzer systems and reagents for the global genetic testing market. In conjunction with our merger, we raised $1.6 million in private funding. We had no material business operations at the time that we acquired BioCal Technology.
The merger caused BioCal to become a wholly-owned subsidiary of eGene, a dormant, publicly held Nevada corporation. The terms of the merger provided that eGene exchange one of its shares of common stock for every three outstanding shares of common stock of BioCal and one of its options to acquire shares of common stock of eGene for every three outstanding options to acquire common stock of BioCal. The combination was a "reverse merge". The transaction was accounted for as a recapitalization of BioCal wherein the net assets are brought forward at their net book value with no goodwill recognized, and the pre-merger financial statements of BioCal became the historical financial statements of the combined company.
The directors and executive officers of BioCal subsequently became the directors and officers of the reorganized entity. Our Centroid Nevada corporation has changed its name to eGene, Inc.
Wow, what a run! STTK could do the same thing. Its also a bird flu stock!!!!!
The patent:
(from the patent orifice)
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=/netahtml/search...
If eGene was,in fact, formerly BioCal, then that checks out...
imo
dyodd
Does anyone have a link to the patent listing?eom
Awesome PR and PPs move. Was distracted with other issues and totally missed it.
I'm sure I'll be hearing from those of you that didn't miss it! LOL!
Followers
|
6
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
135
|
Created
|
03/23/06
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |